



October 28, 2013

AnGes MG, Inc.

Notice Regarding Revisions to Full-Year Business Forecasts

AnGes MG Inc. (“AnGes”) at the board of directors meeting held on October 28, 2013, decided to revise its business forecasts for the fiscal year ending December 31, 2013 (from January 1, 2013 to December 31, 2013) announced on February 7, 2013.

1. Revisions to consolidated business forecasts for the current fiscal year
(January 1, 2013 to December 31, 2013)

Yen in millions

	Net sales	Operating income	Ordinary income	Net income	Net income per share (yen)
Previous forecasts (A)	350~450	(1,200)~ (900)	(1,200)~ (900)	(1,300)~ (1,000)	(4,325.70)~ (3,327.46)
Revised forecasts (B)	450~550	(1,400)~ (1,200)	(1,400)~ (1,200)	(1,450)~ (1,250)	(4,824.82)~ (4,159.32)
Increase/decrease (B-A)	100	(200)~ (300)	(200)~ (300)	(150)	
Percentage change (%)	28.6%~ 22.2%	—	—	—	
(Ref.) Previous results (Fiscal year ended Dec. 2012)	444	(1,785)	(1,716)	(1,708)	(6,767.09)

2. Reasons for revisions

Net sales are expected to increase because the revenue from research and development grew steadily and sales of Mucopolysaccharidosis\Drug “Naglazyme®” is strong.

On the other hand, as increase in research and development expenses are expected resulting from increase in costs associated with research and development progress of “Collatogene®,” NF-kB decoy and CIN therapeutic vaccine which are the Company’s major projects, loss on sales, operating loss, ordinary loss and net loss are likely to increase. Therefore, the initial forecasts have been revised as shown above.

A portion of fees for the global Phase 3 Trial of “Collatogene®” for peripheral cardiovascular disease which are expected to be incurred in the future and upfront

payments from the Company's partner Mitsubishi Tanabe Pharma Corporation are not included in the above business forecasts. The effect is currently being assessed, and an announcement will be made promptly if the business forecasts are revised.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGes MG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 http://www.anges-mg.com Email:info@anges-mg.com</p>
